These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20057395)

  • 1. Matchmaking service links up researchers to wallflower drugs.
    Schubert C
    Nat Med; 2010 Jan; 16(1):7. PubMed ID: 20057395
    [No Abstract]   [Full Text] [Related]  

  • 2. Future pharmaceutical research: the need to look beyond science.
    Seeger S
    Future Med Chem; 2014 May; 6(7):721-3. PubMed ID: 24941866
    [No Abstract]   [Full Text] [Related]  

  • 3. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large drug firms narrow their therapeutic interests.
    Mullard A
    Lancet; 2014 May; 383(9932):1873. PubMed ID: 24892171
    [No Abstract]   [Full Text] [Related]  

  • 6. Combating the cons of consolidation.
    Nat Rev Drug Discov; 2009 Mar; 8(3):177. PubMed ID: 19263592
    [No Abstract]   [Full Text] [Related]  

  • 7. Pfizer's home remedy.
    Abkowitz A
    Fortune; 2009 Aug; 160(4):82-4, 86. PubMed ID: 19728588
    [No Abstract]   [Full Text] [Related]  

  • 8. Mads Krogsgaard Thomsen. Interview by Asher Mullard.
    Thomsen MK
    Nat Rev Drug Discov; 2014 Feb; 13(2):96-7. PubMed ID: 24481301
    [No Abstract]   [Full Text] [Related]  

  • 9. Organizational effectiveness: a key to R&D productivity.
    Tollman P; Panier V; Dosik D; Biondi P; Cuss F
    Nat Rev Drug Discov; 2016 Jul; 15(7):441-2. PubMed ID: 27312725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precompetitive consortia in biomedicine--how are we doing?
    Mittleman B; Neil G; Cutcher-Gershenfeld J
    Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770
    [No Abstract]   [Full Text] [Related]  

  • 11. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 12. Can emerging drug classes improve R&D productivity?
    Meier C; Cairns-Smith S; Schulze U
    Drug Discov Today; 2013 Jul; 18(13-14):607-9. PubMed ID: 23702084
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cohorts and registers: Which public/private partnerships to choose?].
    Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
    Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
    [No Abstract]   [Full Text] [Related]  

  • 14. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Into the valley of death: research to innovation.
    Hudson J; Khazragui HF
    Drug Discov Today; 2013 Jul; 18(13-14):610-3. PubMed ID: 23402848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare.
    Wellenreuther R; Keppler D; Mumberg D; Ziegelbauer K; Lessl M
    Drug Discov Today; 2012 Nov; 17(21-22):1242-8. PubMed ID: 22521665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Industry is more alarmed about reproducibility than academia.
    Bespalov A; Barnett AG; Begley CG
    Nature; 2018 Nov; 563(7733):626. PubMed ID: 30487623
    [No Abstract]   [Full Text] [Related]  

  • 18. David Haslam. Interview by Asher Mullard.
    Haslam D
    Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
    [No Abstract]   [Full Text] [Related]  

  • 19. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN; Williams CS; Arrowsmith JE
    Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The stakes of pre- and post-market authorization development and clinical assessment].
    Schwebig A
    Presse Med; 2012 May; 41 Suppl 1():S6-8. PubMed ID: 22483770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.